{"entity":{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","aka":["MTA Cooperative PRMT5 inhibitor","AMG 193"],"tldr":"Anvumetostat is an experimental small-molecule drug from Amgen in phase 2 trials for non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).","summary":"Anvumetostat is a small-molecule drug developed by Amgen. Its target is PRMT5 (MTAP-deleted cancers). The sponsor states: Anvumetostat (AMG 193) is an MTA-cooperative PRMT5 inhibitor, formulated as an oral film-coated tablet, studied in MTAP-deleted/null advanced NSCLC and other solid tumours. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer. The largest, NCT05094336, plans to enrol 329 participants (actual) with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Anvumetostat","url":"https://clinicaltrials.gov/search?intr=Anvumetostat"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["prmt5-mtap"],"drugs":[],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05094336","nct06593522"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Anvumetostat (AMG 193) is an MTA-cooperative PRMT5 inhibitor, formulated as an oral film-coated tablet, studied in MTAP-deleted/null advanced NSCLC and other solid tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/anvumetostat/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"trial":[{"id":"nct06593522","kind":"trial","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","route":"/trials/nct06593522/"},{"id":"nct05094336","kind":"trial","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","route":"/trials/nct05094336/"}]}}